Diabetes Prevention Program Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study is intended to demonstrate that we can actually deliver the Diabetes Prevention Program intervention well and to show that it is likely effective. We will use results from this pilot study to support our application to The National Institute of Health. NIH is asking for health care centers to show ways to provide this treatment at a reasonable cost. We propose to demonstrate successful and sustainable use DPP's lifestyle intervention in a primary care health care setting (University of Rochester Primary Care).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Diabetes Prevention Programs

NCT01409889

Pre Diabetes Diabetes

COMPLETED NA

CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes

NCT07140848

PreDiabetes

NOT_YET_RECRUITING NA

Diabetes Self-Management & Support LIVE

NCT02040038

Diabetes Mellitus, Type 2

COMPLETED NA

BRInging the Diabetes Prevention Program to GEriatric Populations - PILOT

NCT03524404

Diabetes

COMPLETED NA

Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program

NCT01085682

Type 2 Diabetes

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Subject will be randomly assigned to work with providers at Clinton Medical Associates

Group Type ACTIVE_COMPARATOR

DPP

Intervention Type BEHAVIORAL

1. The primary outcome measure is weight loss with a goal of 7% of initial weight.
2. Secondary outcomes are adherence to behavior changes:

1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
2. Fat intake less than 25% and saturated fat less than 10%
3. Fiber intake of at least 25 grams per day
4. Fasting blood sugar \< 100 mg/dL
5. Absence of tobacco use

2

Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125

Group Type ACTIVE_COMPARATOR

DPP

Intervention Type BEHAVIORAL

1. The primary outcome measure is weight loss with a goal of 7% of initial weight.
2. Secondary outcomes are adherence to behavior changes:

1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
2. Fat intake less than 25% and saturated fat less than 10%
3. Fiber intake of at least 25 grams per day
4. Fasting blood sugar \< 100 mg/dL
5. Absence of tobacco use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DPP

1. The primary outcome measure is weight loss with a goal of 7% of initial weight.
2. Secondary outcomes are adherence to behavior changes:

1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
2. Fat intake less than 25% and saturated fat less than 10%
3. Fiber intake of at least 25 grams per day
4. Fasting blood sugar \< 100 mg/dL
5. Absence of tobacco use

Intervention Type BEHAVIORAL

DPP

1. The primary outcome measure is weight loss with a goal of 7% of initial weight.
2. Secondary outcomes are adherence to behavior changes:

1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
2. Fat intake less than 25% and saturated fat less than 10%
3. Fiber intake of at least 25 grams per day
4. Fasting blood sugar \< 100 mg/dL
5. Absence of tobacco use

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years
* BMI \>24 kg/m2 (\>22 kg/m2 among Asian Americans)
* IGT (2-h plasma glucose 140\~199 mg/dl based on 75-g OGTT if available). The OGTT will not be required for inclusion, but the CMA practitioners may wish to recommend the OGTT for their patients.
* Elevated FPG (95\~125 mg/dl\*).
* HDL-triglyceride ration \> 3.5.

Exclusion Criteria

* Diabetes at baseline
* FPG \>126 mg/dl\*
* 2-h plasma glucose \>200 mg/dl based on 75-g OGTT, if available. OGTT will not be required (see above note).
* Diabetes diagnosed by a physician and confirmed by other clinical data, other than during pregnancy.
* Ever used antidiabetic medication, other than during pregnancy
* Medical conditions likely to limit life span and/or increase risk of intervention
* Cardiovascular disease
* Hospitalization for treatment of heart disease in past 6 months New York Heart Association Functional Class\> 2
* Left bundle branch block or third degree AV block Aortic stenosis
* Systolic blood pressure\> 180 mmHg or diastolic blood pressure\> 105 mmHg
* Cancer requiring treatment in the past 5 years, unless the prognosis is considered good
* Renal disease (creatinine GFR \< or = 30 ml/hr or \> 2.0 mg/dl if GFR not available).
* Anemia (hematocrit \<36% in men or \<33% in women)
* Hepatitis (based on history or serum transaminase elevation)
* Other gastrointestinal disease (pancreatitis, acute inflammatory bowel disease)
* Recent or significant abdominal surgery
* Pulmonary disease with dependence on oxygen or daily use of bronchodilators
* Chronic infection (e.g., HIV, active tuberculosis)
* Conditions or behaviors likely to affect conduct of the trial
* Unable to communicate with clinic staff (e.g., read and speak English).
* Unwilling to accept treatment assignment by randomization
* Participation in another intervention research project that might interfere with DPP
* Weight loss of \> 10% in past 6 months for any reason except postpartum weight loss
* Unable to walk 0.25 miles in 10 min
* Currently pregnant or within 3 months postpartum
* Currently nursing or within 6 weeks of having completed nursing
* Pregnancy anticipated during the course of the trial
* Unwilling to undergo pregnancy testing or report possible pregnancy promptly
* Unwilling to take adequate contraceptive measures, if potentially fertile
* Major psychiatric disorder, including severe active major depression, severe anxiety, schizophrenia, manic depression, bi-polar disorder
* Excessive alcohol intake, either acute or chronic
* Medications and medical conditions likely to confound the assessment for diabetes including:

* Niacin, in doses indicated for lowering serum triglycerides
* Glucocorticoids, systemic
* Other prescription weight-loss medications
* Active Thyroid disease, suboptimally treated as indicated by abnormal serum thyroid-stimulating hormone
* Other endocrine disorders (e.g., Cushing's syndrome, acromegaly)
* Fasting plasma triglyceride \>600 mg/dl, despite treatment

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes